It is used to relieve cough associated with both acute and chronic bronchitis.
First layer (controlled release):Active ingredient: Levodropropizine 45.0 mg
Excipients: Microcrystalline cellulose, Kollidon® SR, Hydroxypropyl cellulose, Magnesium stearate
Second layer (immediate release):
Active ingredient: Levodropropizine 45.0 mg
Excipients: Lactose hydrate, Microcrystalline cellulose, Sodium starch glycolate, Magnesium stearate
Cough associated with acute and chronic bronchitis.
Adults: 1 tablet (equivalent to 90 mg levodropropizine) taken orally twice daily.
As this is a prolonged-release formulation, the tablet must not be split or crushed — it should be taken whole.
Patients with hypersensitivity to this drug or any of its components
Patients with increased bronchial mucus secretion
Patients with mucociliary dysfunction (e.g., Kartagener syndrome or primary ciliary dyskinesia)
Pregnant women, women who may be pregnant, or breastfeeding mothers
Patients with severe hepatic impairment
This product contains lactose and should not be used in patients with hereditary conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
Patients with severe heart failure or severe renal impairment
Elderly patients
Pediatric patients (see section 4 “General Warnings”)
Drowsiness may rarely occur; therefore, caution is advised when driving or operating machinery. This effect may be enhanced when taken with alcohol.
Since this is a prolonged-release formulation, it should not be used in pediatric patients. In such cases, an alternative formulation that allows dose adjustment is recommended.
Use with caution in sensitive patients when taken together with sedative medications.
Do not use in pregnant women, women who may be pregnant, or breastfeeding mothers.
Keep out of reach of children
Do not transfer to another container, as this may lead to misuse or deterioration of the product quality
Store in a tightly closed container at room temperature (1–30°C).
